Physician profile
Yan G Makeyev
NPI 1386812253
$2,651.49
in general payments reported to CMS, 2019-2025
34 companies · $298 in 2025
The $298 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $81.43 · 2021: $430 · 2022: $517 · 2023: $596 · 2024: $281 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,033 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,033.07 |
| Education | $142.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $310.62 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Astrazeneca Pharmaceuticals LP | $231.99 | 2020-2025 | Imfinzi, Enhertu |
| Genentech USA, INC. | $229.78 | 2022-2024 | Lunsumio, Columvi, Polivy |
| Seagen INC. | $190.92 | 2021-2023 | Adcetris |
| Edwards Lifesciences Corporation | $168.40 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbott Laboratories | $147.45 | 2022 | |
| Novartis Pharmaceuticals Corporation | $122.27 | 2022-2024 | |
| Verastem, INC. | $121.78 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.48 | 2022-2024 | |
| Novocure INC. | $106.10 | 2021 | |
| Astellas Pharma US INC | $99.00 | 2021 | |
| Pfizer INC. | $76.99 | 2019-2023 | |
| Amgen INC. | $70.71 | 2019-2023 | Kyprolis |
| Alexion Pharmaceuticals, INC. | $70.61 | 2021-2024 | Ultomiris |
| Exelixis INC. | $68.34 | 2019-2024 | Cabometyx |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $46.71 | 2019 | |
| Csl Behring | $46.40 | 2021-2022 | |
| Medtronic USA, INC. | $44.61 | 2019 | |
| Glaxosmithkline, LLC. | $43.92 | 2022-2025 | Ojjaara |
| Janssen Biotech, INC. | $42.88 | 2019-2023 | Darzalex, Tecvayli |
| Takeda Pharmaceuticals U.S.A., INC. | $39.90 | 2019 | |
| Merck Sharp & Dohme LLC | $38.64 | 2021-2022 | |
| Inspire Medical Systems, INC. | $24.33 | 2025 | Inspire |
| Gilead Sciences, INC. | $23.26 | 2019 | |
| Sobi, INC | $22.71 | 2025 | |
| Immunocore Limited | $20.64 | 2025 | Kimmtrak |
| Genzyme Corporation | $20.56 | 2023 | |
| Abbvie INC. | $19.95 | 2022 | |
| Taiho Oncology, INC. | $17.28 | 2019 | |
| Agios Pharmaceuticals, INC. | $15.38 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $14.70 | 2023 | Epkinly, Imbruvica |
| Ipsen Biopharmaceuticals, INC | $14.62 | 2019 | |
| Chiesi USA, INC. | $12.75 | 2023 | Ferriprox |
| Celgene Corporation | $11.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yan Makeyev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.